| __timestamp | Dynavax Technologies Corporation | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 612613000000 |
| Thursday, January 1, 2015 | 22180000 | 650773000000 |
| Friday, January 1, 2016 | 37257000 | 619061000000 |
| Sunday, January 1, 2017 | 27367000 | 628106000000 |
| Monday, January 1, 2018 | 64770000 | 717599000000 |
| Tuesday, January 1, 2019 | 74986000 | 964737000000 |
| Wednesday, January 1, 2020 | 79256000 | 875663000000 |
| Friday, January 1, 2021 | 100156000 | 886361000000 |
| Saturday, January 1, 2022 | 131408000 | 997309000000 |
| Sunday, January 1, 2023 | 152946000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Unveiling the hidden dimensions of data
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Takeda Pharmaceutical Company Limited and Dynavax Technologies Corporation have shown contrasting approaches to SG&A cost management.
From 2014 to 2023, Takeda's SG&A expenses have consistently been higher, averaging around 823 billion yen annually. In contrast, Dynavax has maintained a leaner structure, with average annual expenses of approximately 71 million dollars. This stark difference highlights Takeda's expansive operations compared to Dynavax's more focused approach.
Interestingly, while Takeda's SG&A costs have grown by about 72% over the period, Dynavax's expenses have surged by over 760%, reflecting its aggressive growth strategy. As of 2023, Takeda's expenses reached a peak of 1.05 trillion yen, while Dynavax's hit 153 million dollars. The data suggests that while Takeda manages a larger scale, Dynavax is rapidly expanding its footprint.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Takeda Pharmaceutical Company Limited
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Dynavax Technologies Corporation
Operational Costs Compared: SG&A Analysis of Pfizer Inc. and Takeda Pharmaceutical Company Limited
SG&A Efficiency Analysis: Comparing Sanofi and Dynavax Technologies Corporation
Takeda Pharmaceutical Company Limited vs Ascendis Pharma A/S: SG&A Expense Trends
Takeda Pharmaceutical Company Limited vs Opthea Limited: SG&A Expense Trends
Takeda Pharmaceutical Company Limited vs Viridian Therapeutics, Inc.: SG&A Expense Trends
argenx SE and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Dynavax Technologies Corporation
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Dynavax Technologies Corporation